trending Market Intelligence /marketintelligence/en/news-insights/trending/b37y35r9VjIOGIcVBm8irw2 content esgSubNav
In This List

Pfizer to invest, collaborate with BioInvent International

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Pfizer to invest, collaborate with BioInvent International

Pfizer Inc. is investing $6 million in BioInvent International AB, a Swedish biotech developing treatments for cancer.

The pharma giant will purchase 21,973,594 shares representing 7.2% of the company for 2.56 Swedish kronor apiece to help the company raise funds for continued research.

Furthermore, Pfizer will pay another $4 million in early and up-front payment in exchange for the exclusive right to develop and commercialize any antibodies generated.

BioInvent can further receive over $500 million in milestone-related payments assuming that five antibodies are developed through to commercialization. The biotech company will also receive royalties on sales of any potential products that may result as a result of the collaboration.

As of Dec. 20, US$1 was equivalent to 9.37 Swedish kronor.